Skip to main content
Equibles
GILD logo

GILD · Gilead Sciences, Inc. · Earnings Call Transcripts & Audio

Track GILD — free

Use GILD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GILD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$145.65 -0.99 (-0.68%) At close · Sep 9
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$182.74B
Shares
1.24B

Gilead Sciences, Inc. Earnings Call Transcripts

Quarterly earnings calls for Gilead Sciences, Inc. (GILD), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼5.1% $7.04B $1.79B '22 Q3 22-10-27 ▲2% $7.39B $1.64B '22 Q4 23-02-02 ▼3.6% $6.35B $1.01B '23 Q1 23-04-27 ▲5.4% $6.60B $1.04B '23 Q2 23-08-03 ▲0.1% $7.05B $2.18B '23 Q3 23-11-07 ▼3.7% $7.11B $1.43B '23 Q4 24-02-06 ▲5.3% $6.69B −$4.17B '24 Q1 24-04-25 ▲5.4% $6.95B $1.61B '24 Q2 24-08-08 ▲7% $7.54B $1.25B '24 Q3 24-11-06 ▲6.4% $7.57B $1.78B '24 Q4 25-02-11 ▼0.3% $6.67B $1.31B '25 Q1 25-04-24 ▲1.8% $7.08B $1.96B '25 Q2 25-08-07 ▲3% $7.77B $3.05B '25 Q3 25-10-30 ▲4.7% $7.92B $2.18B '25 Q4 26-02-10 ▲4.4% $6.96B $2.02B '26 Q1 26-05-07 LATEST ▲10.2% $7.80B −$10.50B '26 Q2 26-08-04
Conference
Investor event
2026-09-15
Gilead Sciences, Inc. (GILD) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Gilead Sciences, Inc. (GILD) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Gilead Sciences, Inc. (GILD) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Confident tone HIV portfolio performance HIV pipeline and weekly oral regimens Trodelvi oncology growth
Revenue
$7.80B
▲ 10.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Gilead Sciences, Inc. (GILD) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-28
Gilead Sciences, Inc. (GILD) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Confident tone HIV franchise growth and pipeline Cell therapy and anitocel launch Business development and acquisitions
Revenue
$6.96B
▲ 4.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Gilead Sciences, Inc. (GILD) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-10
Gilead Sciences, Inc. (GILD) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-03
Gilead Sciences, Inc. (GILD) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-10
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Confident tone HIV business growth and Biktarvy YES2GO HIV prevention launch Oncology and Trodelvy expansion
Revenue
$7.92B*
▲ 4.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2025-11-19
Gilead Sciences, Inc. (GILD) November 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-10-30
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
Confident tone HIV franchise growth Yeztugo launch Oncology pipeline
Revenue
$7.77B
▲ 3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript
Confident tone HIV franchise performance Yeztugo (lenacapavir) launch Trodelvy in metastatic TNBC
Revenue
$7.08B
▲ 1.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript
Confident tone HIV franchise and Biktarvy growth Lenacapavir for PrEP launch Trodelvy and oncology pipeline
Revenue
$6.67B
▼ 0.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Confident tone HIV franchise growth and leadership Lenacapavir for HIV prevention Pipeline depth and long-term growth outlook
Revenue
$7.57B*
▲ 6.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Confident tone Lenacapavir for HIV PrEP Oncology and cell therapy HIV franchise performance
Revenue
$7.54B
▲ 7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript
Confident tone HIV prevention (lenacapavir / PURPOSE) Oncology - Trodelvy Long-acting HIV pipeline
Revenue
$6.95B
▲ 5.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript
Confident tone HIV franchise performance and growth Liver disease and Celadelpar Trodelvy and oncology
Revenue
$6.69B
▲ 5.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
Positive tone Oncology portfolio expansion Trodelvi EVOKE-01 trial outcome 2024 clinical catalysts and pipeline updates
Revenue
$7.11B*
▼ 3.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript
Revenue
$7.05B
▲ 0.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript
Revenue
$6.60B
▲ 5.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript
Revenue
$6.35B
▼ 3.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Gilead Sciences, Inc. (GILD) Q4 2022 Earnings Call Transcript
Revenue
$7.39B*
▲ 2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Gilead Sciences, Inc. (GILD) Q3 2022 Earnings Call Transcript
Revenue
$7.04B
▼ 5.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Gilead Sciences, Inc. (GILD) Q2 2022 Earnings Call Transcript
Revenue
$6.26B
▲ 0.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Gilead Sciences, Inc. (GILD) Q1 2022 Earnings Call Transcript
Revenue
$6.59B
▲ 2.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-01
Gilead Sciences, Inc. (GILD) Q4 2021 Earnings Call Transcript
Revenue
$7.24B*
▼ 2.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Gilead Sciences, Inc. (GILD) Q3 2021 Earnings Call Transcript
Revenue
$7.42B
▲ 12.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Gilead Sciences, Inc. (GILD) Q2 2021 Earnings Call Transcript
Revenue
$6.22B
▲ 20.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Gilead Sciences, Inc. (GILD) Q1 2021 Earnings Call Transcript
Revenue
$6.42B
▲ 15.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Gilead Sciences, Inc. (GILD) Q4 2020 Earnings Call Transcript
Revenue
$7.42B
▲ 26.2% YoY
Gross margin
79.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Gilead Sciences, Inc. (GILD) Q3 2020 Earnings Call Transcript
Revenue
$6.58B
▲ 17.4% YoY
Gross margin
81.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Gilead Sciences, Inc. (GILD) Q2 2020 Earnings Call Transcript
Revenue
$5.14B
▼ 9.5% YoY
Gross margin
77.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Gilead Sciences, Inc. (GILD) Q1 2020 Earnings Call Transcript
Revenue
$5.55B
▲ 5.1% YoY
Gross margin
81.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-04
Gilead Sciences, Inc. (GILD) Q4 2019 Earnings Call
Revenue
$5.88B
▲ 1.4% YoY
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–36 of 36 earnings calls
Key facts CIK 882095 CUSIP 375558103 13F (30d) 828 filings 788 filers Visit website Investor relations